Evidence-dense health optimization

Subscribe
Health Canon
Browse

Environmental Health

PFAS in NHANES: What U.S. Blood Levels Show Over Time

Nearly everyone has detectable PFAS. Legacy compounds fell hard after phase-downs—replacements did not erase exposure.

BY ELENA VOSS 4 MIN READ 3 SOURCES
Environmental Health Lab vial and clean water glass editorial still life, no people
Illustration: Health Canon
In short

CDC NHANES has measured serum PFAS since 1999–2000: nearly all Americans have detectable levels. Legacy PFOS fell >85% and PFOA >70% by 2018–2019 after phase-downs. NASEM tiers (~98% ≥2 ng/mL; ~9% ≥20 ng/mL in 2017–2018) guide clinical follow-up intensity—not panic.

PFAS debates need a population yardstick. NHANES supplies that yardstick: who has what in serum, how levels moved after industrial phase-downs, and how clinical guidance maps percentiles onto follow-up intensity.

This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.

What does NHANES actually measure for PFAS?

NHANES is a nationally representative biomonitoring program reporting serum PFAS in multi-year cycles, typically for ages 12 and older in many tables. Results live in CDC’s National Report on Human Exposure to Environmental Chemicals.

Near-universal detection is the headline ATSDR fact. That means background exposure is systemic—water, food packaging, products, and legacy environmental reservoirs—not a rare occupational oddity.

How did population levels change after phase-downs?

Legacy long-chain compounds show steep declines: PFOS down more than 85 percent and PFOA more than 70 percent from 1999–2000 to 2018–2019. Those are among the clearest public-health success metrics in environmental chemistry.

Success is incomplete. Replacement chemistries, contaminated sites, AFFF history, and consumer products keep PFAS relevant. Newer NHANES analytes can show high detection even as classic compounds fall.

Key reference points
MetricFigure / note
NHANES PFAS start1999–2000
Near-universal detectionATSDR: nearly all U.S.
PFOS change to 2018–19>85% decline
PFOA change to 2018–19>70% decline
≥2 ng/mL (2017–18 map)~98%
≥20 ng/mL (2017–18 map)~9%

How do NASEM tiers connect population data to clinics?

NASEM 2022 guidance links serum sum categories to graded clinical evaluation. ATSDR’s clinician pages translate those tiers into practical prompts—more intensive assessment as levels climb, including cancer-oriented symptom checks in higher tiers for specified ages.

The 98 percent and 9 percent population fractions above 2 and 20 ng/mL (2017–2018 mapping) explain why most people land in some follow-up band while only a minority hit the highest tier.

What should individuals do with this information?

Benchmark labs to NHANES, reduce high-leverage exposures (contaminated water filtration, product choices), and avoid equating detectability with imminent disease. Occupational and community hotspots deserve targeted investigation.

Track updates as new NHANES cycles publish. Do not freeze 2010s numbers forever. Primary sources—ATSDR, CDC tables, NASEM—beat secondary social summaries.

Sources: ATSDR PFAS facts and stats; CDC Exposure Report data tables; NASEM 2022 PFAS clinical guidance.

Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Sources & citations

  1. ATSDR — ATSDR PFAS facts and stats
  2. CDC — CDC Exposure Report data tables
  3. NASEM — NASEM 2022 PFAS clinical guidance

Frequently asked

Questions & answers

Does nearly everyone in the U.S. have PFAS in blood?
Yes according to CDC and ATSDR summaries of NHANES biomonitoring: nearly all people in the United States have detectable PFAS. That is a population exposure fact, not a personal diagnosis. Detection is not the same as clinical disease, and absolute risk depends on which compounds, concentration, duration, and co-factors.
How much did legacy PFOS and PFOA fall after phase-downs?
ATSDR reports that from the 1999–2000 NHANES cycle to 2018–2019, blood PFOS fell more than 85 percent and PFOA more than 70 percent as U.S. production and major uses were reduced after about 2002. Declines prove policy and market shifts can move body burden—but replacement PFAS and residual sources remain.
What are the NASEM serum tiers used clinically?
NASEM guidance, summarized by ATSDR for clinicians, uses summed specified PFAS cut points near under 2 ng/mL, 2 to under 20 ng/mL, and 20 ng/mL or higher to scale follow-up intensity. Mapping 2017–2018 NHANES, roughly 98 percent of the represented population was at or above 2 ng/mL and about 9 percent at or above 20 ng/mL for the specified sum.
How should a patient interpret a commercial PFAS blood test?
Compare the same analytes and units (usually ng/mL) against cycle-matched NHANES geometric means and percentiles, not against a single internet chart. Highly exposed workers and AFFF-impacted communities can sit far above NHANES medians. Clinical decisions belong with clinicians using NASEM-style frameworks, not self-diagnosis from one number.
Why do newer PFAS still appear if legacy levels fell?
Industrial chemistry shifted toward shorter-chain and alternative PFAS after long-chain phase-downs. NHANES panels expand over time and have begun reporting additional analytes with substantial detection fractions. Population averages for classic PFOS/PFOA can fall while total fluorinated exposure remains a moving target. This is general editorial context, not individualized medical advice; match decisions to clinical care when stakes are high.
Is NHANES useful for community water investigations?
Yes as the national comparator. Community biomonitoring after water contamination should use matching analytes, units, and age strata when possible. NHANES is not a pure 'unexposed' control—it is the general U.S. reference distribution that already includes widespread low-level exposure. This is general editorial context, not individualized medical advice; match decisions to clinical care when stakes are high.